# Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

**Authors:** Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Anthony Tolcher

PMC · DOI: 10.3389/fonc.2024.1544394 · Frontiers in Oncology · 2025-01-31

## Full-text entities

- **Genes:** PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, CNGB1 (cyclic nucleotide gated channel subunit beta 1) [NCBI Gene 1258] {aka CNCG2, CNCG3L, CNCG4, CNG4, CNGB1B, GAR1}
- **Diseases:** tumors (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11826311/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11826311/full.md

---
Source: https://tomesphere.com/paper/PMC11826311